FindTrial
Sign In

Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer

A Phase I/II Dose Finding Trial of the Intravenous Injection of CV787, a Prostate-Specific Antigen Cytolytic Adenovirus, in Patients With Hormone Refractory Metastatic Prostate Cancer

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00116155
Enrollment
Unknown
Registered
2005-06-28
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Hormone Refractory Metastatic Prostate Cancer

Brief summary

This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer. Patients will receive treatment intravenously at one of up to nine dose levels, each containing three to six patients.

Interventions

BIOLOGICALCV787 (CG7870)

Sponsors

Cell Genesys
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Design outcomes

Primary

MeasureTime frame
To determine the safety, tolerability, and the maximum tolerated dose of CG7870 when administered intravenously to patients with progressive metastatic hormone refractory prostate cancer—

Secondary

MeasureTime frame
To evaluate prostate-specific antigen (PSA) response rates, duration of response, and time to disease progression—
To evaluate other clinical efficacy responses observed—
To evaluate the systemic pharmacokinetics of CG7870 after intravenous administration—
To monitor the immune response to CG7870—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026